Lalit Pallan

1.0k total citations
19 papers, 451 citations indexed

About

Lalit Pallan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Lalit Pallan has authored 19 papers receiving a total of 451 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Immunology. Recurrent topics in Lalit Pallan's work include Cancer Immunotherapy and Biomarkers (9 papers), CAR-T cell therapy research (3 papers) and Immune Cell Function and Interaction (3 papers). Lalit Pallan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), CAR-T cell therapy research (3 papers) and Immune Cell Function and Interaction (3 papers). Lalit Pallan collaborates with scholars based in United Kingdom, Australia and United States. Lalit Pallan's co-authors include Philip J. Johnson, Roberto Benini, Latha Kadalayil, Andrew K. Burroughs, Tim Meyer, Richard Fox, Laura Marelli, Daniel H. Palmer, Allan Hackshaw and James O’Beirne and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Lalit Pallan

17 papers receiving 447 citations

Peers

Countries citing papers authored by Lalit Pallan

Since Specialization

Citations

This map shows the geographic impact of Lalit Pallan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lalit Pallan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lalit Pallan more than expected).

Fields of papers citing papers by Lalit Pallan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lalit Pallan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lalit Pallan. The network helps show where Lalit Pallan may publish in the future.

Co-authorship network of co-authors of Lalit Pallan

This figure shows the co-authorship network connecting the top 25 collaborators of Lalit Pallan. A scholar is included among the top collaborators of Lalit Pallan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lalit Pallan. Lalit Pallan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Immune checkpoint inhibitor-induced inflammatory arthritis 2025 ·Clinical Medicine ·Benjamin A. Fisher, (unknown), Shirish Dubey, Kulveer Mankia, Arthur G. Pratt, Lalit Pallan	0
2	Lag3 and PD-1 pathways preferentially regulate NFAT-dependent TCR signalling programmes during early CD4+ T cell activation 2024 ·PubMed ·Lozan Sheriff, Alastair Copland, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Elizabeth Jinks, Lalit Pallan, David Bending	1
3	1129P Clinical outcomes from a tebentafusp UK expanded access program in patients with metastatic uveal melanoma (mUM) 2024 ·Annals of Oncology ·(unknown), (unknown), (unknown), (unknown), Andrew Furness, (unknown), Lalit Pallan, Leila Khoja, Patricio Serra-Bellver, (unknown), (unknown), Gopalasamy Reuben Clements, (unknown), Toby Talbot, Jenny Nobes, (unknown), Heather Shaw	2
4	AB1860 CHARACTERISTICS OF IMMUNE CHECKPOINT INHIBITOR INDUCED SICCA SYNDROME 2023 ·Annals of the Rheumatic Diseases ·Trevor F. Cox, Ami V. Desai, Rachel M. Brown, T. S. Bates, Saba Nayar, (unknown), Lalit Pallan, Neil Steven, B Fisher	0
5	CDK4/6 inhibitors in metastatic breast cancer, a comparison of toxicity and efficacy across agents in a real-world dataset 2023 ·Journal of Oncology Pharmacy Practice ·(unknown), Lalit Pallan, (unknown), Leila Khoja	13
6	Eosinophilic Asthma Secondary to Adjuvant Anti-PD-1 Immune Checkpoint Inhibitor Treatment in a Melanoma Patient 2022 ·SHILAP Revista de lepidopterología ·(unknown), B. C. S. Sutton, (unknown), Lalit Pallan, Neil Steven, Leila Khoja	6
7	The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases: A multicenter cohort study. 2022 ·Journal of Clinical Oncology ·Roger Olofsson Bagge, (unknown), Tina J. Hieken, Jonathan S. Zager, Georgina V. Long, Alexander Christopher Jonathan Van Akkooi, Giorgos C. Karakousis, Lalit Pallan, John T. Vetto, David Gyorki, Paolo A. Ascierto, Reinhard Dummer, Jane Yuet Ching Hui, Jacob Schachter, Hildur Helgadóttir, Hidde M. Kroon, Luke D. Rothermel, Matteo S. Carlino, Kristy K. Broman, Lars Ny	1
8	Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case series 2022 ·Journal of Oncology Pharmacy Practice ·(unknown), Leila Khoja, Lalit Pallan, Neil Steven	4
9	Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti–PD-1 therapy 2021 ·European Journal of Cancer ·Adriana Hepner, Victoria Atkinson, James Larkin, Rebecca A. Burrell, Matteo S. Carlino, Douglas B. Johnson, Lisa Zimmer, Katy K. Tsai, Oliver Klein, Serigne Lo, Andrew Haydon, Prachi Bhave, Megan Lyle, Lalit Pallan, Inês Pires da Silva, Camille L. Gérard, Olivier Michielin, Georgina V. Long, Alexander M. Menzies	9
10	Circulating tumour DNA (ctDNA) in metastatic melanoma, a systematic review and meta-analysis 2021 ·European Journal of Cancer ·(unknown), Yi Pan, Eshetu G. Atenafu, Douglas G. Ward, (unknown), Lalit Pallan, (unknown), Leila Khoja	29
11	Discrepancies in response and immune-related adverse events (irAE) of anti-PD-1 monotherapy between races and primary sites in patients (pts) with advanced nonacral cutaneous melanoma (NACM). 2021 ·Journal of Clinical Oncology ·Xue Bai, Alexander N. Shoushtari, Allison Betof Warner, Henry T. Quach, Christopher Cann, Michael Zhang, Lalit Pallan, (unknown), Lu Si, Bixia Tang, Chuanliang Cui, Michelle S. Kim, Tatyana Sharova, Keith T. Flaherty, Georgina V. Long, Alexander M. Menzies, Ryan J. Sullivan, Genevieve M. Boland, Douglas B. Johnson, Jun Guo	1
12	Melanoma recurrence after adjuvant targeted therapy: A multicenter analysis. 2020 ·Journal of Clinical Oncology ·Prachi Bhave, Lalit Pallan, Victoria Atkinson, Justine V. Cohen, Vanna Chiarion‐Sileni, Marta Nyakas, Katharina C. Kaehler, Elizabeth Ruth Plummer, Paolo A. Ascierto, Lisa Zimmer, Célèste Lebbé, Andrea Maurichi, Caroline Robert, Thierry Lesimple, Sapna P. Patel, Judith M. Versluis, Muhammad Adnan Khattak, André van der Westhuizen, Matteo S. Carlino, Andrew Haydon	3
13	Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapy 2019 ·Annals of Oncology ·Adriana Hepner, Matteo S. Carlino, Douglas B. Johnson, Camille L. Gérard, Serigne Lo, Lalit Pallan, (unknown), Olivier Michielin, Georgina V. Long, Alexander M. Menzies	1
14	The association between PD-L1 expression, EGFR mutation and ALK translocation in a series of 982 lung cancers 2017 ·Annals of Oncology ·Matthew Evans, Brendan O’Sullivan, Matthew R. Smith, (unknown), Nicola Trim, (unknown), Lalit Pallan, Philippe Tanière	4
15	A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer 2013 ·Annals of Oncology ·Latha Kadalayil, Roberto Benini, Lalit Pallan, James O’Beirne, Laura Marelli, Dominic Yu, Allan Hackshaw, Richard Fox, Philip J. Johnson, Andrew K. Burroughs, Daniel H. Palmer, Tim Meyer	249
16	Macrophage migration inhibitory factor and DJ-1 in gastric cancer: differences between high-incidence and low-incidence areas 2012 ·British Journal of Cancer ·Neil J. Shimwell, Douglas G. Ward, Yasuhiko Mohri, (unknown), Lalit Pallan, Mabel Teng, Yuichiro Miki, M. Kusunoki, Olga Tucker, Wenbin Wei, (unknown), Philip J. Johnson	10
17	Early B blasts acquire a capacity for Ig class switch recombination that is lost as they become plasmablasts 2011 ·European Journal of Immunology ·Jennifer L. Marshall, Yang Zhang, Lalit Pallan, Mei‐Chi Hsu, Mahmood Khan, Adam F. Cunningham, Ian C. M. MacLennan, Kai‐Michael Toellner	37
18	ANCA-associated vasculitis: from bench research to novel treatments 2009 ·Nature Reviews Nephrology ·Lalit Pallan, Caroline O. S. Savage, Lorraine Harper	11
19	Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia 2007 ·Blood ·Eduardo Olavarría, Shamyla Siddique, Mike Griffiths, Sharon Avery, Jenny Byrne, Karen Piper Hanley, Anne Lennard, Lalit Pallan, Julie Arrazi, Jolanta B. Perz, Derville O’Shea, John M. Goldman, Jane F. Apperley, Charles Craddock	70

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact